Investment Rating - The investment rating for the company is "Buy" [4][9] Core Views - The company achieved a revenue of 22.82 billion yuan in 2023, representing a year-on-year growth of 7.26%, with a net profit attributable to shareholders of 4.30 billion yuan, up 10.14% year-on-year [1] - In Q1 2024, the company reported a revenue of 5.99 billion yuan, a year-on-year increase of 9.2%, and a net profit of 1.37 billion yuan, reflecting a growth of 10.48% year-on-year [1] - The revenue from innovative drugs reached 10.64 billion yuan in 2023, growing by 22.1% year-on-year, accounting for 46.61% of total revenue [1] - The company has a rich pipeline in oncology and has expanded its research into various therapeutic areas including autoimmune diseases, pain management, cardiovascular diseases, metabolic diseases, infectious diseases, respiratory diseases, hematological diseases, and neurological diseases [2] - The company maintained a high level of R&D investment, totaling 6.15 billion yuan in 2023, with 4.95 billion yuan classified as expensed R&D [3] - The company has established five licensing agreements in 2023, with a total transaction value exceeding 4 billion USD, indicating a strong commitment to international collaboration [3] Summary by Sections Financial Performance - In 2023, the company reported a basic earnings per share (EPS) of 0.68 yuan, an increase of 11.48% year-on-year [1] - The company’s total revenue for 2023 was 22.82 billion yuan, with a net profit of 4.30 billion yuan [1] - For Q1 2024, the basic EPS was 0.21 yuan, reflecting a year-on-year growth of 10.53% [1] R&D and Product Pipeline - The company has 14 applications for new drug listings accepted by NMPA in 2023, with 12 progressing to Phase III clinical trials and 35 to Phase II [2] - The company’s innovative drugs are expected to drive future revenue growth due to their significant efficacy and improved accessibility through national insurance coverage [1][2] Market Position and Strategy - The company is recognized as a leading innovative drug enterprise in China, with a comprehensive and rational R&D layout [7] - The company’s internationalization strategy is progressing steadily, with ongoing efforts to seek partnerships with global pharmaceutical leaders [3]

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected return exceeding 10% relative to the CSI 300 index over the next six months [10][13]. Core Insights - The company is a leader in the micro-motor sector, focusing on the production and sales of micro-motors and fans, with a strong presence in the cold chain motor and external rotor fan markets. It has established partnerships with notable clients such as PANASONIC and WHIRLPOOL [13]. - The company is expected to achieve revenues of CNY 1.269 billion, CNY 1.521 billion, and CNY 1.882 billion from 2023 to 2025, with corresponding net profits of CNY 120 million, CNY 331 million, and CNY 422 million [10][12]. - The ECM motor segment is anticipated to grow significantly due to energy efficiency policies, with the company positioned as a domestic leader in this area [13]. Financial Data and Valuation - Revenue (CNY million): 2021A: 1,111.61, 2022A: 1,204.77, 2023E: 1,269.39, 2024E: 1,521.41, 2025E: 1,882.22 [2]. - Growth Rate (%): 2021A: 39.27%, 2022A: 8.38%, 2023E: 5.36%, 2024E: 19.85%, 2025E: 23.72% [2]. - Net Profit (CNY million): 2021A: 254.43, 2022A: 307.93, 2023E: 120.36, 2024E: 331.08, 2025E: 422.10 [2]. - Earnings Per Share (CNY): 2021: 1.11, 2022: 1.34, 2023E: 0.52, 2024E: 1.44, 2025E: 1.84 [2]. - Price-to-Earnings Ratio (PE): 2023E: 41.69, 2024E: 15.15, 2025E: 11.89 [2]. - Price-to-Book Ratio (PB): 2023E: 3.13, 2024E: 2.79, 2025E: 2.45 [2]. - Return on Equity (ROE %): 2023E: 7.51%, 2024E: 18.42%, 2025E: 20.64% [2].

◆ ◆ ◆ ◆ ...

◆ ◆ ◆ ◆ ◆ ◆ ...

公司网址:www.avicsec.com 联系电话:010-59219558 传真:010-59562637 2024年04月23日 正券研究报告|宏观研究|宏观深度 金融市场分析周报 (2024.04.15-2024.04.19) 报告摘要 | --- | --- | --- | --- | --- | |-----------------------------------------------|----------------------------------------------------------------|-------|--------------------------------------------------------------------------------------------|-----------| | | | | | | | | | | 主要数据 | | | ● | 经济数据:春节效应消退后,经济复苏速度开始明显放缓,多数经济指 | | 上证指数 | 3021.9775 | | | | | 沪深 300 | 3506.2249 | | | 标低于市场预期 ...

中航证券研究所发布 1 ◆ 农药周期波动、行业竞争加剧等风险。 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |--------------------------------|----------------|---------------------------|----------------|-----------------|------------------|----------|----------|----------|----------------| | 资产负债表 | | 長与财务指标(单位:百万元) | | | 利润表 | | | | [证券研究报告] | | 会计年度 | 2023 | 2024E | 2025E | 2026E | 会计年度 | 2023 | 2024E | 2025E | 2026E | | 货币资金 | 864.09 | 1726.60 | 1956.27 | 2250.26 | 营业收入 | 10459.62 | 11510.68 | 13041.81 | 15001.75 | | ...

Investment Rating - The investment rating for the company is "Buy" with a target price of 27.00 yuan, indicating an expected return of over 10% relative to the CSI 300 index in the next six months [24][34]. Core Insights - The company achieved record-high revenue and profit in 2023, with revenue of 544 million yuan (+49.93%) and net profit of 90 million yuan (+349.61%). The first quarter of 2024 also showed strong performance with revenue of 161 million yuan (+41.76%) and net profit of 32 million yuan (+153.27%) [3][24]. - The international business, particularly in aviation engine components, is growing rapidly, with a projected increase in LEAP engine shipments by 20-25% in 2024, which will drive further revenue growth [27]. - The company is expanding its production capacity and optimizing its product structure, which is expected to enhance profitability and operational efficiency [10][30]. Summary by Sections Financial Performance - In Q1 2024, the company reported a revenue of 161 million yuan, a 41.76% increase year-on-year, and a net profit of 32 million yuan, reflecting a 153.27% increase [3]. - For the full year 2023, the company achieved a revenue of 544 million yuan (+49.93%) and a net profit of 90 million yuan (+349.61%), marking the highest figures in the last five years [24][34]. Business Segments - The aviation products segment saw a revenue growth of 50.86%, while the medical products segment grew by 37.18%. The revenue contributions from aviation and medical products were 89.13% and 9.95%, respectively [6]. - The international engine components business generated 270 million yuan in revenue, a 68.27% increase, accounting for 49.67% of total revenue [7]. Operational Efficiency - The company improved its cash flow management, with net cash flow from operating activities reaching 121 million yuan, up from 52 million yuan in the previous year [6]. - The gross margin improved to 35.99% (+6.29 percentage points), and the net margin increased to 16.10% (+10.97 percentage points) due to enhanced production efficiency and product maturity [24][34]. Future Outlook - The company is expected to maintain strong growth, with projected revenues of 713 million yuan, 869 million yuan, and 1.017 billion yuan for 2024, 2025, and 2026, respectively [34]. - The expansion of production capacity and the introduction of new products are anticipated to support sustained revenue growth and profitability [10][30].

◆ ◆ ◆ ◆ ...

2024年04月20 证券研究报告|策略研究|策略点评 | --- | --- | --- | --- | --- | --- | |-----------|--------------|-------------------------------------------------------|------------------------------------------------------------|---------------------------|-------------------------------------------------------------| | | | | | | | | 报告摘要 | | | | 作者 | | | 核心观点: | | | | 董忠云 | 分析师 | | | | | ◆ 3月经济呈现弱复苏态势,结构分化,有喜有忧。制造业投资在设 | | SAC执业证书: S0640515120001 | | | | | 备更新等政策拉动下表现超预期,基建增速稳定,地产投资继续磨 | | 联系电话：010-59562478 邮箱:dongzy@avicse ...

◆ 安德利 乖宝宠物 海大集团 苏垦农发 中宠股份 涨幅前五 18.4% 10.9% 10.4% 5.2% 4.8% 中基健康 朗源股份 福建金森 雪榕生物 正虹科技 跌幅前五 -21.0% -19.1% -19.0% -16.5% -16.0% ◆ ◆ ...